Microlyse - TargED Biopharmaceuticals
Alternative Names: TGD-001Latest Information Update: 06 May 2024
At a glance
- Originator University Medical Center Utrecht
- Developer TargED Biopharmaceuticals
- Class Anticoagulants; Recombinant fusion proteins; Single-domain antibodies; Vascular disorder therapies
- Mechanism of Action Plasminogen activators; Platelet aggregation inhibitors; Von Willebrand factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Stroke; Thrombotic thrombocytopenic purpura
Most Recent Events
- 06 May 2024 TargED Biopharmaceuticals Pipeline, May 2024: TGD 001 added as synonym; as all description for the candidate matches with the description mentioned on the pipeline as discussed with SME; Thes request sent
- 22 Feb 2022 Preclinical trials in Stroke in Netherlands (IV)
- 22 Feb 2022 Preclinical trials in Thrombotic thrombocytopenic purpura in Netherlands (IV)